Therapy Areas: Inflammatory Diseases
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
15 September 2025 - Biotechnology company Kodiak Sciences Inc (Nasdaq: KOD) announced on Monday that new data from its Phase 1b APEX study of KSI-101 showed rapid and clinically meaningful vision gain...
Onco3R Therapeutics receives Belgian regulatory approval for clinical trial of novel SIK3 inhibitor
5 September 2025 - Onco3R Therapeutics, a Belgium-based clinical-stage immunology and oncology biotech company, announced on Thursday the approval of a clinical trial application by the Belgian regula...
Mesoblast agrees option to issue USD50m of convertible notes
4 September 2025 - Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a developer of allogeneic cellular medicines for inflammatory diseases, announced on Wednesday that it has entered into convertible note su...
LPOXY agrees financing to fund registrational STOP-Cdiff trial
4 September 2025 - LPOXY Therapeutics Inc, a clinical-stage biopharmaceutical company developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced on Wed...
Resolution Therapeutics reports first patient dosed in Phase I/II EMERALD study
4 September 2025 - Resolution Therapeutics, a UK-based clinical-stage biopharmaceutical company involved in Regenerative Macrophage Therapy (RMT) to treat inflammatory and fibrotic diseases, announced...
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
25 August 2025 - Biotechnology company Coya Therapeutics Inc (NASDAQ: COYA) announced on Monday that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) applica...